Valuation : SELLAS Life Sciences Group, Inc.

Market Cap 2.67B 2.3B 2.17B 1.98B 3.69B 252B 3.72B 25.69B 9.97B 129B 10.03B 9.81B 424B P/E 2026 *
-64.5x
P/E 2027 * -139x
Enterprise Value 2.67B 2.3B 2.17B 1.98B 3.69B 252B 3.72B 25.69B 9.97B 129B 10.03B 9.81B 424B EV / Sales 2026 *
-
EV / Sales 2027 * 50.3x
Free-Float
99.08%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : SELLAS Life Sciences Group, Inc.

1 day+4.65%
1 week+0.22%
Current month+3.15%
1 month+22.64%
3 months+65.19%
6 months+172.48%
Current year+264.99%
1 week 12.64
Extreme 12.6401
15.56
1 month 9.8
Extreme 9.8
15.67
Current year 3.23
Extreme 3.23
15.88
1 year 1.39
Extreme 1.39
15.88
3 years 0.5
Extreme 0.4986
15.88
5 years 0.5
Extreme 0.4986
15.88
10 years 0.5
Extreme 0.4986
554.5
Manager TitleAgeSince
Chief Executive Officer 50 29/12/2017
Director of Finance/CFO 41 30/12/2017
Compliance Officer - -
Director TitleAgeSince
Director/Board Member 50 29/12/2017
Chairman 66 01/06/2024
Director/Board Member 69 29/12/2017
Date Insider Type Main position Quantity % Market Cap. Importance
07/01/26 Free

Executive/Senior Manager

300,000 0.2106%
07/01/26 Free

Director

50,000 0.0351%
07/01/26 Free

Chief Financial Officer

300,000 0.2106%
Change 5-day change 1-year change 3-year change Capi.($)
+4.12%+0.22%+651.91%+855.56% 2.67B
+1.03%-3.11%+39.80%+94.60% 68.21B
+1.62%+0.33%+48.61%+89.64% 64.25B
+1.77%-1.03%-15.27%+366.86% 26.54B
+1.28%-8.38%+2.49%-15.47% 25.61B
+1.30%+0.74%+31.66%-18.33% 19.88B
-0.38%-12.42%+224.86%+373.18% 17.13B
+0.65%-5.83%+1.44%+544.44% 14.93B
+1.74%+3.01%+55.43%+159.50% 14.1B
+0.91%+0.49%+24.17%+193.51% 12.45B
Average +1.45%-3.99%+106.51%+264.35% 26.58B
Weighted average by Cap. +1.24%-3.04%+48.25%+160.48%

Financials

2026 *2027 *
Net sales - 53.09M 45.8M 43.15M 39.31M 73.48M 5.02B 74.03M 511M 198M 2.56B 199M 195M 8.42B
Net income -38.3M -33.04M -31.12M -28.36M -53M -3.62B -53.4M -368M -143M -1.85B -144M -141M -6.08B -21.38M -18.44M -17.37M -15.83M -29.59M -2.02B -29.81M -206M -79.82M -1.03B -80.27M -78.52M -3.39B
Net Debt - -
Logo SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
Employees
-
Date Price Change Volume
02/09/26 $13.70 +3.61% 3,420,610
01/09/26 $13.22 -0.90% 5,911,666
31/08/26 $13.34 +0.98% 7,449,605
28/08/26 $13.21 -13.15% 9,825,411
27/08/26 $15.21 +10.78% 12,117,377
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
13.22USD
Average target price
32.50USD
Spread / Average Target
+145.84%

Quarterly revenue - Rate of surprise